Hyperlipidemia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024–2034, estimated DelveInsight

Hyperlipidemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hyperlipidemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Hyperlipidemia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Hyperlipidemia, historical and forecasted epidemiology as well as the Hyperlipidemia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Hyperlipidemia Market by downloading the comprehensive report from DelveInsight @ Hyperlipidemia Drugs Market Landscape

 

Key Takeaways from the Hyperlipidemia Market Report

  • In September 2024:- Novartis Pharmaceuticals-This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to <12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
  • In September 2024:- Merck Sharp & Dohme LLC- This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
  • According to data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018, the prevalence of hypercholesterolemia (total cholesterol ≥ 240 mg/dL) was found to be 11.5%, translating to an estimated 12.05 million Americans. Additionally, the prevalence of hypertriglyceridemia (triglyceride levels ≥ 200 mg/dL) was reported at 10.4%, or about 10.84 million Americans.
  • As per the research by Ramírez et al. (2020), 33.8% of the population presented any of the forms of hyperlipidemias, being more frequent in men (50.6%) than in women (28.8%).
  • As per our analysis, primary hyperlipidemia is more prevalent in the US compared to Japan, with the US showing a higher proportion of individuals affected due to genetic factors and broader diagnostic efforts.
  • As per our analysis, the prevalence of hyperlipidemia in the US varies significantly by age group. It is rare in children under two years, but may occur if they are underweight or obese, resulting in secondary pediatric hyperlipidemia. Among young adults (20-39), 11.3% are affected, reflecting relatively lower risk. Prevalence increases to 15.1% in middle-aged adults (40-59) due to lifestyle and metabolic factors. In older adults (60+), 76% are affected, with many remaining undiagnosed or untreated.
  • The leading Hyperlipidemia Companies such as Novartis Pharmaceuticals, Beijing Suncadia Pharmaceuticals Co., Ltd, NewAmsterdam Pharma, Daewoong Pharmaceutical Co. LTD., Hasten Biopharmaceutical Co., Ltd., Arrowhead Pharmaceuticals, Visirna Therapeutics HK Limited, Ionis Pharmaceuticals, Inc., and others.
  • Promising Hyperlipidemia Therapies such as Pelacarsen (TQJ230) 80 mg s.c., SHR-1918, Evolocumab, Statins (Cardiovascular Agents), Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg, and others.

 

Gain a competitive edge in the Hyperlipidemia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Hyperlipidemia Treatment Drugs

 

Hyperlipidemia Epidemiology Segmentation in the 7MM

  • Hyperlipidemia Diagnosed Prevalent Cases
  • Hyperlipidemia Etiology-specific Diagnosed Prevalent Cases
  • Hyperlipidemia Gender-specific Diagnosed Prevalent Cases
  • Hyperlipidemia Age-specific Diagnosed Prevalent Cases

 

Hyperlipidemia Market Insights

Hyperlipidemia is a medical term for abnormally high levels of fats (lipids) in the blood, which include cholesterol and triglycerides. Although hyperlipidemia can be inherited, it’s most often the result of lifestyle factors, including an unbalanced diet and too little physical activity. If lifestyle changes aren’t enough to treat hyperlipidemia, doctor may prescribe medication.

 

Discover key developments and opportunities in the Hyperlipidemia Market. Click here to learn more from DelveInsight’s latest report @ Hyperlipidemia Market Size

 

Hyperlipidemia Treatment Market

The hyperlipidemia treatment market has experienced steady growth, attributed to rising rates of obesity, sedentary lifestyles, and unhealthy dietary habits, all of which contribute to higher lipid levels in the population. Additionally, the aging population is at a higher risk for hyperlipidemia, further driving the demand for effective treatments. According to market analysis, the demand for hyperlipidemia therapies is expected to increase as patients and healthcare providers emphasize early diagnosis and management to prevent long-term complications.

 

Hyperlipidemia Emerging Drugs

  • SLN360: Silence Therapeutics plc
  • VERVE-101 and VERVE-102: Verve Therapeutics, Inc.

 

Hyperlipidemia Market Driver

The rising incidence of hyperlipidemia, particularly due to sedentary lifestyles, poor dietary habits, and the growing rate of obesity, is a major driver for market growth. Hyperlipidemia has become a common metabolic disorder across the globe, leading to a surge in demand for effective treatments.

 

Hyperlipidemia Market Barrier

The cost of newer lipid-lowering therapies, such as PCSK9 inhibitors, can be prohibitive for many patients, especially in low- and middle-income countries. This high cost can limit patient access to these advanced treatments and act as a barrier to market growth.

 

Download DelveInsight’s Hyperlipidemia Market report today and stay ahead in this rapidly evolving field. @ Hyperlipidemia Clinical Trials

 

Scope of the Hyperlipidemia Market Report

  • Coverage- 7MM
  • Hyperlipidemia Companies- Novartis Pharmaceuticals, Beijing Suncadia Pharmaceuticals Co., Ltd, NewAmsterdam Pharma, Daewoong Pharmaceutical Co. LTD., Hasten Biopharmaceutical Co., Ltd., Arrowhead Pharmaceuticals, Visirna Therapeutics HK Limited, Ionis Pharmaceuticals, Inc., and others.
  • Hyperlipidemia Therapies- Pelacarsen (TQJ230) 80 mg s.c., SHR-1918, Evolocumab, Statins (Cardiovascular Agents), Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg, and others.
  • Hyperlipidemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Hyperlipidemia Unmet Needs, KOL’s views, Analyst’s views, Hyperlipidemia Market Access and Reimbursement

 

Download the report to understand which factors are driving Hyperlipidemia Market Trends @ Hyperlipidemia Market Trends

 

Table of Content

  1. Key Insights
  2. Executive Summary of Hyperlipidemia
  3. Competitive Intelligence Analysis for Hyperlipidemia
  4. Hyperlipidemia: Market Overview at a Glance
  5. Hyperlipidemia: Disease Background and Overview
  6. Patient Journey
  7. Hyperlipidemia Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Hyperlipidemia Unmet Needs
  10. Key Endpoints of Hyperlipidemia Treatment
  11. Hyperlipidemia Marketed Products
  12. Hyperlipidemia Emerging Therapies
  13. Hyperlipidemia: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Hyperlipidemia
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024–2034, estimated DelveInsight

Friedreich’s Ataxia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Friedreich’s Ataxia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Friedreich’s Ataxia, historical and forecasted epidemiology as well as the Friedreich’s Ataxia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Friedreich’s Ataxia Market by downloading the comprehensive report from DelveInsight @ Friedreich’s Ataxia Market

 

Key Takeaways from the Friedreich’s Ataxia Market Report

  • In September 2024:- PTC Therapeutics- An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age. The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
  • In September 2024:- Reata- Friedreich’s ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.
  • Based on a secondary research genetically confirmed Friedreich’s ataxia patient has not been found in the Japanese population, and the majority of patients with Friedreich’s ataxia-like phenotype may be confirmed as AOA1, AOA2, ataxia with vitamin E deficiency or autosomal-recessive spastic ataxia of Charlevoix-Saguenay if examined by genetic testing.
  • According to a study, cases of Friedreich’s ataxia are very rare in Japan. It was observed that among 844 probands with various types of spinocerebellar degeneration reported by approximately 200 major neurological clinics in Japan, there were 26 males and 26 females diagnosed with Friedreich’s ataxia.
  • As per the statistics by National Institute of Neurological Disorders and Stroke, although rare, Friedreich’s ataxia is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset Friedreich’s ataxia is less common, <25% of diagnosed individuals, and can occur anytime during adulthood.
  • According to a study in 2009, Friedreich’s ataxia is the most common of the inherited ataxias across most of Europe. Its prevalence is highest in Western Europe, with more than 1 case per 30,000 individuals (1/30,000) reported in north-west Spain.
  • The leading Friedreich’s Ataxia Companies such as Neurocrine Biosciences, Takeda, Reata Pharmaceuticals Inc., AbbVie, Minoryx Therapeutics S.L., ApoPharma, Metro International Biotech LLC, PTC Therapeutics, Design Therapeutics Inc., Larimar Therapeutics Inc., Veristat Inc., Retrotope Inc., and others.
  • Promising Friedreich’s Ataxia Therapies such as Vatiquinone, Omaveloxolone Capsules, 2.5 mg, and others.

 

Gain a competitive edge in the Friedreich’s Ataxia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Friedreich’s Ataxia Treatment Drugs

 

Friedreich’s Ataxia Epidemiology Segmentation in the 7MM

  • Total Friedreich’s Ataxia Prevalent Cases
  • Friedreich’s Ataxia Diagnosed Prevalent Cases
  • Friedreich’s Ataxia Onset Type Diagnosed Prevalent Cases
  • Friedreich’s Ataxia Age-specific Diagnosed Prevalent cases

 

Friedreich’s Ataxia Market Insights

Friedreich’s Ataxia is an inherited neurodegenerative disease, for which there is only one US FDA-approved treatment. Treatments for Friedreich’s ataxia have targeted specific symptoms of the disease rather than the underlying cause, and to a greater degree, these therapeutic options still make up the gold standard Friedreich’s ataxia care. There is no cure for the disease, but there are ways to manage the condition and improve the quality of life for those living with Friedreich’s ataxia. Fortunately, the most life-threatening symptom in patients with Friedreich’s ataxia, i.e. Heart disease, can be controlled with treatments developed for use in the general population.

 

Discover key developments and opportunities in the Friedreich’s Ataxia Market. Click here to learn more from DelveInsight’s latest report @ Friedreich’s Ataxia Market Size

 

Friedreich’s Ataxia Therapeutics Market Landscape

The Friedreich’s ataxia market in the 7MM (United States, EU4 and the UK, Japan) is poised for growth, driven by increasing awareness of the disease and advancements in genetic testing. Currently, the market is characterized by a limited number of treatment options, with ongoing research and clinical trials exploring novel therapies. The rising prevalnce of Friedreich’s ataxia has led to greater demand for specialized care and support services. Additionally, collaborations between pharmaceutical companies and research institutions are fostering innovation in potential therapies. As awareness continues to grow, the market is expected to attract investment and drive the development of new treatment modalities, ultimately improving patient outcomes.

 

Friedreich’s Ataxia Treatment Market

The Friedreich’s ataxia treatment market goal primarily focuses on managing symptoms, slowing down the progression of the disease, and improving the quality of life for patients. This often involves a multidisciplinary approach, including physical therapy, occupational therapy, speech therapy, and medications to manage symptoms such as slurred speech, muscle stiffness, loss of reflexes, and fatigue. Additionally, research efforts are ongoing to develop therapies that target the underlying genetic cause of the disease, with the ultimate aim of finding a cure.

 

Download DelveInsight’s Friedreich’s Ataxia Market report today and stay ahead in this rapidly evolving field. @ Friedreich’s Ataxia Clinical Trials

 

Scope of the Friedreich’s Ataxia Market Report

  • Coverage- 7MM
  • Friedreich’s Ataxia Companies- Neurocrine Biosciences, Takeda, Reata Pharmaceuticals Inc., AbbVie, Minoryx Therapeutics S.L., ApoPharma, Metro International Biotech LLC, PTC Therapeutics, Design Therapeutics Inc., Larimar Therapeutics Inc., Veristat Inc., Retrotope Inc., and others.
  • Friedreich’s Ataxia Therapies- Vatiquinone, Omaveloxolone Capsules, 2.5 mg, and others.
  • Friedreich’s Ataxia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Friedreich’s Ataxia Unmet Needs, KOL’s views, Analyst’s views, Friedreich’s Ataxia Market Access and Reimbursement

 

Download the report to understand which factors are driving Friedreich’s Ataxia Market Trends @ Friedreich’s Ataxia Market Trends

 

Table of Content

1: Key Insights

2: Report Introduction

3: Friedreich’s Ataxia Market Overview at a Glance

4: Key Events

5: Epidemiology and Market Methodology

6: Executive Summary of Friedreich’s Ataxia

7: Disease Background and Overview: Friedreich’s Ataxia

8: Epidemiology and Patient Population

9: Patient Journey

10: Marketed Therapies

11: Emerging Therapies

12: Friedreich’s Ataxia: 7 Major Market Analysis

13: Key Opinion Leaders’ Views

14: SWOT Analysis

15: Unmet needs

16: Market Access and Reimbursement

  1. Appendix

18: DelveInsight Capabilities

19: Disclaimer

20: About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034

Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Neurogenic Detrusor Overactivity Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Neurogenic Detrusor Overactivity, historical and forecasted epidemiology as well as the Neurogenic Detrusor Overactivity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Neurogenic Detrusor Overactivity Market by downloading the comprehensive report from DelveInsight @ Neurogenic Detrusor Overactivity Market

 

Key Takeaways from the Neurogenic Detrusor Overactivity Market Report

  • The growth of the Neurogenic Detrusor Overactivity Market is expected to be primarily driven by increasing prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies.
  • In September 2024:- Astellas Pharma- A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula-Based Suspension in Children From 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity.
  • In September 2024:- EG 427- First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization.
  • Neurogenic Detrusor Overactivity is estimated to affect 50–90% of patients with multiple sclerosis and 70–84% of patients with SCI.
  • Neurogenic Detrusor Overactivity in children can be caused by various conditions, including transverse myelitis, spinal cord injury, and spina bifida. Spina bifida is the most common cause, affecting 1,500–2,000 of the over 4 million babies born annually in the US.
  • It was found that the prevalence of urinary incontinence was 50.9% in patients with MS, 52.3% with SCI, 33.1% with Parkinson’s disease, and 23.6% with stroke.
  • The prevalence of urinary symptoms in patients with Parkinson’s disease was found to be nearly3% for detrusor hyperreflexia with detrusor-sphincter dyssynergia in Japan.
  • The prevalence of detrusor hyperreflexia in patients with Parkinson’s disease was found to be approximately 7.7% in Italy.
  • The leading Neurogenic Detrusor Overactivity Companies such as Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
  • Promising Neurogenic Detrusor Overactivity Therapies such as Mirabegron, Vibegron, EG110A, and others.

 

Gain a competitive edge in the Neurogenic Detrusor Overactivity Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Neurogenic Detrusor Overactivity Treatment Drugs

 

Neurogenic Detrusor Overactivity Epidemiology Segmentation in the 7MM

  • Total Neurogenic Detrusor Overactivity Prevalent Cases
  • Total Neurogenic Detrusor Overactivity Diagnosed Prevalent Cases
  • Neurogenic Detrusor Overactivity Condition-specific Diagnosed Prevalent Cases
  • Neurogenic Detrusor Overactivity Treated Cases

 

Neurogenic Detrusor Overactivity Market Insights

The primary management of NDO focuses on behavioral approaches, such as increasing the frequency of urination, reducing fluid intake in the evening, avoiding diuretics like caffeine and alcohol, and using absorbent undergarments or bed pads. Pharmacologic treatments are the next step in managing NDO. Anticholinergic medications are commonly used, as they reduce detrusor muscle activation by blocking cholinergic muscarinic receptors. These drugs are available in both oral and transdermal forms, but they are nonspecific and can cause systemic side effects such as dry eyes, dry mouth, and visual disturbances due to ciliary muscle paralysis. Gastrointestinal effects like reduced motility and secretion can result in halitosis, dental caries, and constipation. Additionally, anticholinergic therapy may decrease sweating, which can be particularly problematic for multiple sclerosis patients who already experience heat intolerance.

 

Discover key developments and opportunities in the Neurogenic Detrusor Overactivity Market. Click here to learn more from DelveInsight’s latest report @ Neurogenic Detrusor Overactivity Market Size

 

Neurogenic Detrusor Overactivity Drugs Uptake

  • DYSPORT (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. DYSPORT is approved for the management of urinary incontinence in adults with NDO due to SCI or multiple sclerosis in multiple countries including the UK and others.
  • BOTOX is a neuromuscular blocking agent and acetylcholine release inhibitor used for managing neurogenic detrusor overactivity (NDO) in pediatric patients aged 5 years and older who do not respond adequately to or are intolerant of anticholinergic medications. It is the first neurotoxin approved specifically for this indication.
  • MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ S (mirabegron extended-release oral suspension granules) are beta-3 adrenergic agonists indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older in the US. Additionally, mirabegron is marketed under the brand name BETMIGA for the treatment of NDO.

 

Neurogenic Detrusor Overactivity Emerging Drugs Profile

  • EG110A: EG 427

EG110A is a recombinant herpes simplex virus type 1 (HSV-1)-derived vector that does not replicate and expresses the light chain of botulinum neurotoxin F (BoNT/F-LC) under the control of the human calcitonin gene-related peptide (hCGRP) promoter. It is designed to provide long-term, sensory neuron-selective transgenic expression in bladder afferents.

 

Download DelveInsight’s Neurogenic Detrusor Overactivity Market report today and stay ahead in this rapidly evolving field. @ Neurogenic Detrusor Overactivity Clinical Trials

 

Scope of the Neurogenic Detrusor Overactivity Market Report

  • Coverage- 7MM
  • Neurogenic Detrusor Overactivity Companies- Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
  • Neurogenic Detrusor Overactivity Therapies- Mirabegron, Vibegron, EG110A, and others.
  • Neurogenic Detrusor Overactivity Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Neurogenic Detrusor Overactivity Unmet Needs, KOL’s views, Analyst’s views, Neurogenic Detrusor Overactivity Market Access and Reimbursement

 

Download the report to understand which factors are driving Neurogenic Detrusor Overactivity Market Trends @ Neurogenic Detrusor Overactivity Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Neurogenic Detrusor Overactivity

3. Competitive Intelligence Analysis for Neurogenic Detrusor Overactivity

4. Neurogenic Detrusor Overactivity: Market Overview at a Glance

5. Neurogenic Detrusor Overactivity: Disease Background and Overview

6. Patient Journey

7. Neurogenic Detrusor Overactivity Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Neurogenic Detrusor Overactivity Unmet Needs

10. Key Endpoints of Neurogenic Detrusor Overactivity Treatment

11. Neurogenic Detrusor Overactivity Marketed Products

12. Neurogenic Detrusor Overactivity Emerging Therapies

13. Neurogenic Detrusor Overactivity: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neurogenic Detrusor Overactivity

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Hepatocellular Carcinoma Pipeline Outlook

 

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

  • In September 2024:- Translational Research in Oncology- A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria
  • In September 2024:- Hoffmann-La Roche- This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
  • In September 2024:- Akeso- The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
  • DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
  • The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

 

Stay informed about the cutting-edge advancements in Hepatocellular Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatocellular Carcinoma Clinical Trials Assessment

 

Hepatocellular Carcinoma Emerging Drugs

  • Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Liver Cancer and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

  • SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

  • Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

  • Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

  • STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

 

Learn more about Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatocellular Carcinoma Unmet Needs

 

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
  • Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Hepatocellular Carcinoma Pipeline on our website @ Hepatocellular Carcinoma Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Namodenoson: Can-Fite BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SRF388: Surface Oncology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. STP705: Sirnaomics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hepatocellular Carcinoma Key Companies
  21. Hepatocellular Carcinoma Key Products
  22. Hepatocellular Carcinoma- Unmet Needs
  23. Hepatocellular Carcinoma- Market Drivers and Barriers
  24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
  25. Hepatocellular Carcinoma Analyst Views
  26. Hepatocellular Carcinoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

HER2-Negative Breast Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in HER2-Negative Breast Cancer Research. Learn more about our innovative pipeline today! @ HER2-Negative Breast Cancer Pipeline Outlook

 

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

  • In September 2024:- Borstkanker Onderzoek Groep– This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
  • In September 2024:- RayzeBio Inc.- Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)
  • In September 2024:- Hoffmann-La Roche- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer).
  • DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
  • The leading HER2-Negative Breast Cancer Companies such as Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • Promising HER2 Negative Breast Cancer Therapies such as Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.

 

Stay informed about the cutting-edge advancements in HER2-Negative Breast Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2-Negative Breast Cancer Clinical Trials Assessment

 

HER2-Negative Breast Cancer Emerging Drugs

  • Giredestrant : Genentech

Giredestrant is a novel investigative small molecule that works as selective estrogen receptor degrader (SERD) by targeting the estrogen receptor (ER). The drug candidate is a new molecular entity (NME) which is administered through oral route. Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER. In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes. Currently, the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • Inavolisib : Genentech

Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα. In preclinical models, the molecule showed potent selective inhibition of PI3Kα and has increased potency to mutant PI3K cells over wild type. It is less sensitive for the other three PI3K isoforms. Inavolisib binds to the ATP-binding site of PI3Kα, thereby blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling as shown in preclinical models. Moreover, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduction of pathway activity. Currently the drug is in Phase III stage of its development for the treatment of HER2 negative breast cancer.

  • CX-2009 : CytomX Therapeutics

CX-2009 (Praluzatamab ravtansine) is a conditionally activated antibody-drug conjugate (ADC) comprised of a CD166-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Praluzatamab ravtansine utilizes CytomX Probody® platform technology, which incorporates a masking peptide to cover and block the cellular binding region of the antibody. Tethered to the antibody via a protease-cleavable linker, currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • H3B 6545 : H3 Biomedicine

H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer. H3B- 6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ERα.4 H3B-6545 activity against ERα mutants resistant to standard therapy provides an opportunity to target a currently unmet medical need both as a single agent and in combination with other breast cancer therapies. Currently, the drug is in Phase II stage of its development for the treatment of HER2 negative breast cancer.

  • RGT-419B : Regor Therapeutics

RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B’s tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor. Currently, the drug is in Phase I stage of its development for the treatment of HER2 negative breast cancer.

 

Learn more about HER2-Negative Breast Cancer Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ HER2-Negative Breast Cancer Unmet Needs

 

HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

HER2-Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Discover the latest advancements in HER2-Negative Breast Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the HER2-Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2-Negative Breast Cancer Companies- Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, Phoenix Molecular Designs, and others.
  • HER2 Negative Breast Cancer Therapies- Doxorubicin, Cyclophosphamide, Utidelone Combined with Bevacizumab, Capecitabine, Carboplatin, Cisplatin, and others.
  • HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of H HER2-Negative Breast Cancer Pipeline on our website @ HER2-Negative Breast Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2 Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Giredestrant : Genentech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CX-2009 : CytomX Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RGT-419B : Regor Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HER2 Negative Breast Cancer Key Companies
  21. HER2 Negative Breast Cancer Key Products
  22. HER2 Negative Breast Cancer- Unmet Needs
  23. HER2 Negative Breast Cancer- Market Drivers and Barriers
  24. HER2 Negative Breast Cancer- Future Perspectives and Conclusion
  25. HER2 Negative Breast Cancer Analyst Views
  26. HER2 Negative Breast Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Hepatic Tumor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Hepatic Tumor Research. Learn more about our innovative pipeline today! @ Hepatic Tumor Pipeline Outlook

Key Takeaways from the Hepatic Tumor Pipeline Report

  • In September 2024:- Biotheus Inc.- A Phase Ib/II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of PM8002 Injection Combined With PM1009 Injection in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma.
  • In September 2024:- AstraZeneca- The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
  • DelveInsight’s Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
  • The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Promising Hepatic Tumor Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.

Stay informed about the cutting-edge advancements in Hepatic Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatic Tumor Clinical Trials Assessment

Hepatic Tumor Emerging Drugs Profile

  • Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

  • MTL CEBPA : MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

  • Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

  • Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

  • ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

Learn more about Hepatic Tumor Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatic Tumor Unmet Needs

Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Hepatic Tumor Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Hepatic Tumor Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatic Tumor Pipeline Report

  • Coverage- Global
  • Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Hepatic Tumor Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.
  • Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Hepatic Tumor Pipeline on our website @ Hepatic Tumor Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatic Tumor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. Namodenoson: Can Fite Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MTL CEBPA : MiNA Therapeutics
  12. Early Stage Products (Phase I)
  13. Comparative Analysis
  14. ETN101: Etnova Therapeutics Corp.
  15. Inactive Products
  16. Hepatic Tumor Key Companies
  17. Hepatic Tumor Key Products
  18. Hepatic Tumor – Unmet Needs
  19. Hepatic Tumor – Market Drivers and Barriers
  20. Hepatic Tumor – Future Perspectives and Conclusion
  21. Hepatic Tumor Analyst Views
  22. Hepatic Tumor Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: 9650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/

 

Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

DelveInsight’s, “Stargardt Disease Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Stargardt Disease (STGD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Stargardt Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Stargardt Disease Pipeline Outlook

Key Takeaways from the Stargardt Disease Pipeline Report

  • In August 2024:- Belite Bio Inc.- A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease.
  • DelveInsight’s Stargardt Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
  • The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
  • Promising Stargardt Disease Therapies such as OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.

Stay ahead with the most recent pipeline outlook for Stargardt Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Stargardt Disease Treatment Drugs

Stargardt Disease Emerging Drugs Profile

  • Tinlarebant: Belite Bio

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Stargardt disease.

  • KIO-301: Kiora Pharmaceuticals

KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of stargardt disease.

  • OCU410: Ocugen

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of stargardt disease.

Explore groundbreaking therapies and clinical trials in the Stargardt Disease Pipeline. Access DelveInsight’s detailed report now! @ New Stargardt Disease Drugs

Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Stargardt Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Stargardt Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Stargardt Disease Market Drivers and Barriers

Scope of the Stargardt Disease Pipeline Report

  • Coverage- Global
  • Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
  • Stargardt Disease Therapies- OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
  • Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Stargardt Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Stargardt Disease Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Stargardt Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Stargardt disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tinlarebant: Belite Bio
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. KIO-301: Kiora Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. OCU410: Ocugen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Stargardt disease Key Companies
  21. Stargardt disease Key Products
  22. Stargardt disease -Unmet Needs
  23. Stargardt disease -Market Drivers and Barriers
  24. Stargardt disease -Future Perspectives and Conclusion
  25. Stargardt disease Analyst Views
  26. Stargardt disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: 9650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/

 

Head and Neck Cancer Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

DelveInsight’s, “Head and Neck Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Head and Neck Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Head and Neck Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Head and Neck Cancer Pipeline Outlook

Key Takeaways from the Head and Neck Cancer Pipeline Report

  • In September 2024:- Alentis Therapeutics AG- The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with pembrolizumab in patients with Head and Neck Cancer.
  • In August 2024:- GlaxoSmithKline- The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
  • DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 160+ pipeline therapies for Head and Neck Cancer treatment.
  • The leading Head and Neck Cancer Companies such as Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
  • Promising Head and Neck Cancer Therapies such as RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.

Stay ahead with the most recent pipeline outlook for Head and Neck Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Head and Neck Cancer Treatment Drugs

Head and Neck cancer Emerging Drugs

  • Xevinapant: Debiopharm/Merck
  • Dostarlimab: GlaxoSmithKline
  • Tigilanol tiglate: QBiotics Group Limited
  • MEM-288: Memgen, Inc.

Explore groundbreaking therapies and clinical trials in the Head and Neck Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Head and Neck Cancer Drugs

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Head and Neck Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Head and Neck Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Head and Neck Cancer Market Drivers and Barriers

Scope of the Head and Neck Cancer Pipeline Report

  • Coverage- Global
  • Head and Neck Cancer Companies- Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
  • Head and Neck Cancer Therapies- RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.
  • Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Head and Neck Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Head and Neck Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Head and Neck Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Xevinapant: Debiopharm/Merck
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Tigilanol tiglate: QBiotics Group Limited
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. MEM-288: Memgen, Inc.
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Head and Neck Cancer Key Companies
  20. Head and Neck Cancer Key Products
  21. Head and Neck Cancer – Unmet Needs
  22. Head and Neck Cancer – Market Drivers and Barriers
  23. Head and Neck Cancer – Future Perspectives and Conclusion
  24. Head and Neck Cancer Analyst Views
  25. Head and Neck Cancer Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: 9650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/

 

Triple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Triple Negative Breast Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Triple Negative Breast Cancer Pipeline Outlook

 

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

  • In September 2024:- Merck Sharp & Dohme LLC- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
  • DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

 

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs

 

Triple Negative Breast Cancer Emerging Drugs Profile

  • Camrelizumab: Jiangsu HengRui Medicine
  • SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  • AK117: Akeso Biopharma
  • PLX038: ProLynx
  • PMD-026: Phoenix Molecular Designs

 

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Triple Negative Breast Cancer Drugs

 

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers

 

Scope of the Triple Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
  • Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Triple Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Camrelizumab: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AK117: Akeso Biopharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PMD-026: Phoenix Molecular Designs
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Triple Negative Breast Cancer Key Companies
  18. Triple Negative Breast Cancer Key Products
  19. Triple Negative Breast Cancer- Unmet Needs
  20. Triple Negative Breast Cancer- Market Drivers and Barriers
  21. Triple Negative Breast Cancer- Future Perspectives and Conclusion
  22. Triple Negative Breast Cancer Analyst Views
  23. Triple Negative Breast Cancer Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “Castrate Resistant Prostrate Cancer Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook

Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report

  • In September 2024:- Bayer– A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).

  • DelveInsight’s Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.

  • The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.

  • Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.

Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs

Castrate Resistant Prostrate Cancer Emerging Drugs

  • Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

  • Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs

Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • intravitreal

  • Subretinal

  • Topical.

  • Molecule Type

Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers

Scope of the Castrate Resistant Prostrate Cancer Pipeline Report

  • Coverage- Global

  • Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.

  • Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.

  • Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

  • Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction

  2. Executive Summary

  3. Castrate Resistant Prostrate Cancer: Overview

  4. Pipeline Therapeutics

  5. Therapeutic Assessment

  6. Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective

  7. In-depth Commercial Assessment

  8. Castrate Resistant Prostrate Cancer Collaboration Deals

  9. Late Stage Products (Phase III)

  10. Niraparib: Janseen

  11. Mid Stage Products (Phase II)

  12. ZEN003694: Newsoara Biopharma

  13. Early Stage Products (Phase I)

  14. EPI7386: ESSA Pharma

  15. Pre-clinical and Discovery Stage Products

  16. Drug Name: Company Name

  17. Inactive Products

  18. Castrate Resistant Prostrate Cancer Key Companies

  19. Castrate Resistant Prostrate Cancer Key Products

  20. Castrate Resistant Prostrate Cancer- Unmet Needs

  21. Castrate Resistant Prostrate Cancer- Market Drivers and Barriers

  22. Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion

  23. Castrate Resistant Prostrate Cancer Analyst Views

  24. Castrate Resistant Prostrate Cancer Key Companies

  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Phone: 9650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/